KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 119 filers reported holding KARYOPHARM THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.17 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,304 | -25.5% | 6,944 | -1.9% | 0.00% | – |
| Q2 2023 | $12,491 | -63.9% | 7,079 | -20.5% | 0.00% | – |
| Q1 2023 | $34,643 | +15.5% | 8,906 | 0.0% | 0.00% | – |
| Q4 2022 | $30,000 | +42.9% | 8,906 | +134.3% | 0.00% | – |
| Q3 2022 | $21,000 | +31.2% | 3,801 | +4.3% | 0.00% | – |
| Q2 2022 | $16,000 | -40.7% | 3,644 | +0.1% | 0.00% | – |
| Q1 2022 | $27,000 | -18.2% | 3,642 | -29.0% | 0.00% | – |
| Q4 2021 | $33,000 | -73.4% | 5,132 | -75.8% | 0.00% | – |
| Q3 2021 | $124,000 | -5.3% | 21,235 | +67.1% | 0.00% | – |
| Q2 2021 | $131,000 | -5.8% | 12,705 | -4.1% | 0.00% | – |
| Q1 2021 | $139,000 | -61.3% | 13,251 | -42.8% | 0.00% | -100.0% |
| Q4 2020 | $359,000 | +5.6% | 23,169 | -0.4% | 0.00% | 0.0% |
| Q3 2020 | $340,000 | -28.7% | 23,268 | -7.5% | 0.00% | -50.0% |
| Q2 2020 | $477,000 | +43.2% | 25,168 | +44.9% | 0.00% | +100.0% |
| Q1 2020 | $333,000 | – | 17,368 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $35,031,000 | 23.03% |
| Palo Alto Investors LP | 5,267,652 | $81,543,000 | 4.28% |
| Fairmount Funds Management LLC | 702,351 | $10,872,000 | 3.89% |
| Birchview Capital, LP | 188,000 | $2,910,000 | 1.68% |
| Mesirow Financial Investment Management, Inc. | 22,303 | $345,250,000 | 1.09% |
| EMERALD ADVISERS, LLC | 1,822,781 | $28,217,000 | 0.94% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,661,236 | $25,716,000 | 0.90% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,552,504 | $24,033,000 | 0.85% |
| Altium Capital Management LP | 133,951 | $2,074,000 | 0.77% |
| Hood River Capital Management LLC | 931,754 | $14,424,000 | 0.48% |